A case of Mikulicz's disease (IgG4-related plasmacytic disease) complicated by autoimmune hypophysitis.

in Sjögren’s syndrome with a combination of prednisone and cyclophosphamide. Arch Neurol 2001;58:815–19. 5. Hermisson M, Klein R, Schmidt F, Weller M, Kuler W. Myelopathy in primary Sjögren’s syndrome: diagnostic and therapeutic aspects. Acta Neurol Scand 2002;105:450–3. 6. Hawley RJ, Hendricks WT. Treatment of Sjogren syndrome myelopathy with azathioprine and steroids. Arch Neurol 2002;59:875. 7. Vitali C, Bombardieri S, Moutsopoulos HM, Coll J, Gerli R, Hatron PY, et al. Assessment of the European classification criteria for Sjögren’s syndrome in a series of clinically defined cases: results of a prospective multicentre study. Ann Rheum Dis 1996;55:116–21. 8. Rogers SJ, Williams CS, Román GC. Myelopathy in Sjögren’s syndrome. Role of nonsteroidal immunosuppressants. Drugs 2004;64:123–32. 9. Alexander EL. Neurologic disease in Sjögren’s syndrome: mononuclear inflammatory vasculopathy affecting central/ peripheral nervous system and muscle. Rheum Clin Dis North Am 1993;19:869–908. 10. Alexander EL, Ranzenbach MR, Kumar AJ, Kozachuk WE, Rosenbaum AE, Patronas N, et al. Anti-Ro (SS-A) autoantibodies in central nervous system disease associated with Sjögren’s syndrome (CNS-SS): clinical, neuroimaging, and angiographic correlates. Neurology 1994;44:899–908.